<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article article-type="letter">
  <?properties open_access?>
  <!-- Original-type: sc-->
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id>
      <journal-title>British Journal of Cancer</journal-title>
      <issn pub-type="ppub">0007-0920</issn>
      <issn pub-type="epub">1532-1827</issn>
      <publisher>
        <publisher-name>Nature Publishing Group</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">12771913</article-id>
      <article-id pub-id-type="pmc">2377120</article-id>
      <article-id pub-id-type="pii">6600967</article-id>
      <article-id pub-id-type="doi">10.1038/sj.bjc.6600967</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Short Communication</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Prophylactic options in patients with 5-fluorouracil-associated cardiotoxicity</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Cianci</surname>
            <given-names>G</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Morelli</surname>
            <given-names>M F</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cannita</surname>
            <given-names>K</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Morese</surname>
            <given-names>R</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ricevuto</surname>
            <given-names>E</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Di Rocco</surname>
            <given-names>Z C</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Porzio</surname>
            <given-names>G</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lanfiuti Baldi</surname>
            <given-names>P</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ficorella</surname>
            <given-names>C</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
          <xref ref-type="aff" rid="aff2">2</xref>
          <xref ref-type="corresp" rid="caf1">*</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1"><label>1</label><sup>1</sup>Department of Medical Oncology, S. Salvatore Hospital, University of L'Aquila, 67100 L'Aquila, Italy</aff>
      <aff id="aff2"><label>2</label><sup>2</sup>Department of Experimental Medicine, University of L'Aquila, Via Vetoio, Coppito II, L'Aquila, 67100 Italy</aff>
      <author-notes>
        <corresp id="caf1"><label>*</label>Author for correspondence: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:ficorella@interfree.it">ficorella@interfree.it</email></corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>13</day>
        <month>05</month>
        <year>2003</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <day>19</day>
        <month>05</month>
        <year>2003</year>
      </pub-date>
      <volume>88</volume>
      <issue>10</issue>
      <fpage>1507</fpage>
      <lpage>1509</lpage>
      <history>
        <date date-type="received">
          <day>27</day>
          <month>11</month>
          <year>2002</year>
        </date>
        <date date-type="accepted">
          <day>28</day>
          <month>01</month>
          <year>2003</year>
        </date>
      </history>
      <copyright-statement>Copyright 2003, Cancer Research UK</copyright-statement>
      <copyright-year>2003</copyright-year>
      <permissions>
        <copyright-holder>Cancer Research UK</copyright-holder>
      </permissions>
      <kwd-group>
        <kwd>prophylaxis</kwd>
        <kwd>cardiotoxicity</kwd>
        <kwd>5-fluorouracil</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <p>5-Fluorouracil (5-FU) is an active antimetabolite used in several tumours, such as gastrointestinal tumours, in which the choice of effective alternative drugs is limited (<xref ref-type="other" rid="bib4">Kohne <italic>et al</italic>, 1998</xref>). The spectrum of toxicities associated with 5-FU involves the gastrointestinal tract, the bone marrow, the skin and the central nervous system. Last, but not the least, 5-FU may give cardiac toxicity that is less familiar to physicians and this may present as precordial pain, atrial arrhythmias, electrocardiogram (EKG) ST-T wave changes, ventricular dysfunction and cardiogenic shock.</p>
    <p>The overall incidence of 5-FU cardiotoxicity varies from 1.2 to 18% of patients and is usually underestimated, since silent EKG alterations often occur (<xref ref-type="other" rid="bib3">Klaus Becker <italic>et al</italic>, 1999</xref>). The different mechanisms involved in 5-FU-associated cardiotoxicity are not yet fully understood and no unequivocally effective prophylaxis or treatment for this specific toxicity exists. Here, we describe three cases of 5-FU-associated cardiotoxicity, its clinical management and the prophylactic treatment used.</p>
    <sec sec-type="methods">
      <title>PATIENTS AND METHODS</title>
      <sec>
        <title>Case 1</title>
        <p>A 57-year-old male, with positive family history for acute myocardial infarction (AMI) but with no history of cardiovascular disease, came to our observation after undergoing an anterior resection of the rectum for a stage III rectal&#x2013;sigmoid adenocarcinoma (RSA) (<xref rid="tbl1" ref-type="table">Table 1</xref><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><p content-type="table-title">Clinical and pathological features of patients</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">&#xA0;</th><th align="left" valign="top" charoff="50">Case 1</th><th align="left" valign="top" charoff="50">Case 2</th><th align="left" valign="top" charoff="50">Case 3</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Familiarity</td><td align="left" valign="top" charoff="50">AMI</td><td align="left" valign="top" charoff="50">&#x2014;</td><td align="left" valign="top" charoff="50">&#x2014;</td></tr><tr><td align="left" valign="top" charoff="50">Age</td><td align="left" valign="top" charoff="50">57</td><td align="left" valign="top" charoff="50">65</td><td align="left" valign="top" charoff="50">70</td></tr><tr><td align="left" valign="top" charoff="50">Clinical history</td><td align="left" valign="top" charoff="50">&#x2014;</td><td align="left" valign="top" charoff="50">HBP, diabetes, gastritis</td><td align="left" valign="top" charoff="50">HBP</td></tr><tr><td align="left" valign="top" charoff="50">Tumour size</td><td align="left" valign="top" charoff="50">RSA</td><td align="left" valign="top" charoff="50">Ampulla of Vater</td><td align="left" valign="top" charoff="50">RSA</td></tr><tr><td align="left" valign="top" charoff="50">Phase</td><td align="left" valign="top" charoff="50">Metastatic</td><td align="left" valign="top" charoff="50">Metastatic</td><td align="left" valign="top" charoff="50">Adjuvant</td></tr><tr><td align="left" valign="top" charoff="50">Adjuvant therapy</td><td align="left" valign="top" charoff="50">No</td><td align="left" valign="top" charoff="50">No</td><td align="left" valign="top" charoff="50">Yes</td></tr><tr><td align="left" valign="top" charoff="50">&#x2003;Type</td><td align="left" valign="top" charoff="50">&#x2014;</td><td align="left" valign="top" charoff="50">&#x2014;</td><td align="left" valign="top" charoff="50">5-FU</td></tr><tr><td align="left" valign="top" charoff="50">&#x2003;Procedure</td><td align="left" valign="top" charoff="50">&#x2014;</td><td align="left" valign="top" charoff="50">&#x2014;</td><td align="left" valign="top" charoff="50">Bolus</td></tr><tr><td align="left" valign="top" charoff="50">Advanced therapy</td><td align="left" valign="top" charoff="50">Yes</td><td align="left" valign="top" charoff="50">Yes</td><td align="left" valign="top" charoff="50">No</td></tr><tr><td align="left" valign="top" charoff="50">&#x2003;Type</td><td align="left" valign="top" charoff="50">CPT11/5-FU</td><td align="left" valign="top" charoff="50">CDDP/5-FU</td><td align="left" valign="top" charoff="50">&#x2014;</td></tr><tr><td align="left" valign="top" charoff="50">&#x2003;Procedure</td><td align="left" valign="top" charoff="50">Bolus/continuous infusion</td><td align="left" valign="top" charoff="50">Bolus/continuous infusion</td><td align="left" valign="top" charoff="50">&#x2014;</td></tr><tr><td align="left" valign="top" charoff="50">Symptom</td><td align="left" valign="top" charoff="50">Chest pain</td><td align="left" valign="top" charoff="50">Chest pain</td><td align="left" valign="top" charoff="50">Chest pain</td></tr><tr><td align="left" valign="top" charoff="50">&#x2003;Duration</td><td align="left" valign="top" charoff="50">Few minutes</td><td align="left" valign="top" charoff="50">5&#x2009;min</td><td align="left" valign="top" charoff="50">Few minutes</td></tr><tr><td align="left" valign="top" charoff="50">&#x2003;Cycle</td><td align="left" valign="top" charoff="50">1&#xB0;</td><td align="left" valign="top" charoff="50">1&#xB0;</td><td align="left" valign="top" charoff="50">3&#xB0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x2003;Day</td><td align="left" valign="top" charoff="50">4&#xB0;</td><td align="left" valign="top" charoff="50">4&#xB0;</td><td align="left" valign="top" charoff="50">4&#xB0;</td></tr><tr><td align="left" valign="top" charoff="50">Therapy</td><td align="left" valign="top" charoff="50">Yes</td><td align="left" valign="top" charoff="50">Yes</td><td align="left" valign="top" charoff="50">Yes</td></tr><tr><td align="left" valign="top" charoff="50">&#x2003;Type</td><td align="left" valign="top" charoff="50">Nitroglycerin</td><td align="left" valign="top" charoff="50">Nitroglycerin</td><td align="left" valign="top" charoff="50">Nitroglycerin</td></tr><tr><td align="left" valign="top" charoff="50">Examinations</td><td align="left" valign="top" charoff="50">Yes</td><td align="left" valign="top" charoff="50">Yes</td><td align="left" valign="top" charoff="50">Yes</td></tr><tr><td align="left" valign="top" charoff="50">&#x2003;EKG</td><td align="left" valign="top" charoff="50">Negative</td><td align="left" valign="top" charoff="50">Ischaemic alteration</td><td align="left" valign="top" charoff="50">Negative</td></tr><tr><td align="left" valign="top" charoff="50">&#x2003;EchoCG</td><td align="left" valign="top" charoff="50">No</td><td align="left" valign="top" charoff="50">Reduction of contractility</td><td align="left" valign="top" charoff="50">No</td></tr><tr><td align="left" valign="top" charoff="50">&#x2003;Enzymes</td><td align="left" valign="top" charoff="50">Negative</td><td align="left" valign="top" charoff="50">Not done</td><td align="left" valign="top" charoff="50">Negative</td></tr><tr><td align="left" valign="top" charoff="50">&#x2003;Effort-EKG</td><td align="left" valign="top" charoff="50">No</td><td align="left" valign="top" charoff="50">Ventricular extrasystole</td><td align="left" valign="top" charoff="50">Negative</td></tr><tr><td align="left" valign="top" charoff="50">Other cycles</td><td align="left" valign="top" charoff="50">Yes</td><td align="left" valign="top" charoff="50">Yes</td><td align="left" valign="top" charoff="50">Yes</td></tr><tr><td align="left" valign="top" charoff="50">&#x2003;Number</td><td align="left" valign="top" charoff="50">5</td><td align="left" valign="top" charoff="50">6</td><td align="left" valign="top" charoff="50">3</td></tr><tr><td align="left" valign="top" charoff="50">&#x2003;Procedure</td><td align="left" valign="top" charoff="50">Bolus/continuous infusion</td><td align="left" valign="top" charoff="50">Bolus/continuous infusion</td><td align="left" valign="top" charoff="50">Bolus</td></tr><tr><td align="left" valign="top" charoff="50">&#x2003;Therapy</td><td align="left" valign="top" charoff="50">Nitroglycerin/dose reduction of 5-FU</td><td align="left" valign="top" charoff="50">Nitroglycerin/dose reduction of 5-FU</td><td align="left" valign="top" charoff="50">Weekly therapy</td></tr><tr><td align="left" valign="top" charoff="50">Other symptoms</td><td align="left" valign="top" charoff="50">No</td><td align="left" valign="top" charoff="50">No</td><td align="left" valign="top" charoff="50">No</td></tr><tr><td align="left" valign="top" charoff="50">Other chemotherapy</td><td align="left" valign="top" charoff="50">Yes</td><td align="left" valign="top" charoff="50">No</td><td align="left" valign="top" charoff="50">No</td></tr><tr><td align="left" valign="top" charoff="50">&#x2003;Type</td><td align="left" valign="top" charoff="50">OXP/5-FU</td><td align="left" valign="top" charoff="50">&#x2014;</td><td align="left" valign="top" charoff="50">&#x2014;</td></tr><tr><td align="left" valign="top" charoff="50">&#x2003;Procedure</td><td align="left" valign="top" charoff="50">Bolus/continuous infusion</td><td align="left" valign="top" charoff="50">&#x2014;</td><td align="left" valign="top" charoff="50">&#x2014;</td></tr><tr><td align="left" valign="top" charoff="50">Symptoms</td><td align="left" valign="top" charoff="50">No</td><td align="left" valign="top" charoff="50">&#x2014;</td><td align="left" valign="top" charoff="50">&#x2014;</td></tr><tr><td align="left" valign="top" charoff="50">Other cycles</td><td align="left" valign="top" charoff="50">Yes</td><td align="left" valign="top" charoff="50">&#x2014;</td><td align="left" valign="top" charoff="50">&#x2014;</td></tr><tr><td align="left" valign="top" charoff="50">&#x2003;Number</td><td align="left" valign="top" charoff="50">6</td><td align="left" valign="top" charoff="50">&#x2014;</td><td align="left" valign="top" charoff="50">&#x2014;</td></tr><tr><td align="left" valign="top" charoff="50">&#x2003;Procedure</td><td align="left" valign="top" charoff="50">Bolus/continuous infusion</td><td align="left" valign="top" charoff="50">&#x2014;</td><td align="left" valign="top" charoff="50">&#x2014;</td></tr><tr><td align="left" valign="top" charoff="50">&#x2003;Therapy</td><td align="left" valign="top" charoff="50">Nitroglycerin</td><td align="left" valign="top" charoff="50">&#x2014;</td><td align="left" valign="top" charoff="50">&#x2014;</td></tr></tbody></table><table-wrap-foot><fn id="tbfnote1"><label/><p>AMI=acute myocardial infarction; CPT11=irinotecan; EKG=electrocardiogram; echoCG=echocardiogram; CDDP=cisplatin; OXP=oxaliplatin; 5-FU=5-fluorouracil; HBP=high blood pressure; RSA=rectal&#x2013;sigmoid adenocarcinoma.</p></fn></table-wrap-foot></table-wrap>). Physical examination, chest X-rays, blood pressure and EKG were all within normal limits. The patient received four cycles of adjuvant chemotherapy with 5-FU (370&#x2009;mg&#x2009;m<sup>&#x2212;2</sup>&#x2009;day<sup>&#x2212;1</sup>) and folinic acid (FA) (50&#x2009;mg&#x2009;tot<sup>&#x2212;1</sup>) i.v. for 5 days, every 3 weeks.</p>
        <p>During adjuvant chemotherapy, disease progressed with liver metastasis and the patient's therapy was changed to irinotecan (180&#x2009;mg&#x2009;m<sup>&#x2212;2</sup>) day 1 and 5-Fu 12-h flat continuous infusion from 22.00 to 10.00&#x2009;h (5-FU 12-h c.i.) (900&#x2009;mg&#x2009;m<sup>&#x2212;2</sup>&#x2009;day<sup>&#x2212;1</sup>) for 4 days, every 2 weeks. Approximately 93&#x2009;h after starting the first cycle of the second 5-FU regimen, the patient presented angina-like pain that lasted a few minutes and disappeared with oral nitroglycerin. The blood pressure was 160/115&#x2009;mmHg and the heart rate was 105 beats&#x2009;min<sup>&#x2212;1</sup> (b.p.m.). During the anginal attack, EKG recordings and serum cardiac enzyme measurements were normal; therefore, the same chemotherapy infusion schedule was continued, but the dose of 5-FU was reduced to 800&#x2009;mg&#x2009;m<sup>&#x2212;2</sup>&#x2009;day<sup>&#x2212;1</sup> and transepidermal nitroglycerin prophylaxis was administered during 5-FU 12-h c.i. The patient then received a further five cycles of this treatment without any chest pain. Upon disease progression, the patient received six cycles of oxaliplatin (100&#x2009;mg&#x2009;m<sup>&#x2212;2</sup>) day 1 and 5-FU 12-h c.i. (800&#x2009;mg&#x2009;m<sup>&#x2212;2</sup>&#x2009;day<sup>&#x2212;1</sup>) for 4 days, every 2 weeks always associated with prophylactic transepidermal nitroglycerin. No angina-like syndrome recurred and no EKG changes were noted.</p>
      </sec>
      <sec>
        <title>Case 2</title>
        <p>A 65-year-old male with high blood pressure (HBP), diabetes and gastritis came to our attention with abdominal lymphatic and pulmonary metastases from an ampulla of Vater adenocarcinoma (<xref rid="tbl1" ref-type="table">Table 1</xref>). He received one cycle of induction chemotherapy containing cisplatin (CDDP) (100&#x2009;mg&#x2009;m<sup>&#x2212;2</sup>) day 1 and 5-FU 12-h c.i. (1000&#x2009;mg&#x2009;m<sup>&#x2212;2</sup>&#x2009;day<sup>&#x2212;1</sup>) for 5 days, every 3 weeks. Approximately 95&#x2009;h after beginning the first cycle of 5-FU infusion, the patient referred several episodes of anginal pain, associated with sweating, that disappeared with oral nitroglycerin. On day 5 of cycle I, the blood pressure was 130/80&#x2009;mmHg, the heart rate was 104&#x2009;b.p.m. and the EKG recorded shortly after pain remission showed ischaemic alterations. The patient was admitted to the hospital and immediately subjected to an echocardiogram that revealed a reduction in inferior and posterolateral contractility and an altered left ventricle diastolic release with an ejection fraction of 56%. The EKG recorded the following day showed a T-alteration in the anterolateral leads and a nonspecific ST segment elevation in the inferior leads. At 4 days after the pain episode, the EKG showed a T-alteration in the lateral leads, likely due to an AMI with ischaemic alterations. The effort-EKG obtained on the same day was interrupted at 80% of the maximum because ventricular extrasystole bigeminis rised. The patient was subjected to CT-scan for restaging of disease. This showed a 50% reduction of pulmonary metastases and disappearance of abdominal lymphatic metastasis. For this reason, the same chemotherapy infusion schedule was continued, but the dose of 5-FU was reduced to 800&#x2009;mg&#x2009;m<sup>&#x2212;2</sup>&#x2009;day<sup>&#x2212;1</sup>. Transepidermal nitroglycerin was administered during 5-FU infusion and chemotherapy was administered while the patient recovered at the hospital. The dose of 5-FU for the cycles thereafter was increased to 900&#x2009;mg&#x2009;m<sup>&#x2212;2</sup>&#x2009;day<sup>&#x2212;1</sup> with transepidermal nitroglycerin administration during 5-FU infusion. The patient received a further four cycles of this treatment, in an outpatient setting, and no longer complained of anginal pain.</p>
      </sec>
      <sec>
        <title>Case 3</title>
        <p>A 70-year-old female with HBP presented at our hospital with stage II RSA (<xref rid="tbl1" ref-type="table">Table 1</xref>). She received three cycles of adjuvant chemotherapy with bolus 5-FU (370&#x2009;mg&#x2009;m<sup>&#x2212;2</sup>&#x2009;day<sup>&#x2212;1</sup>) and FA (50&#x2009;mg&#x2009;tot<sup>&#x2212;1</sup>&#x2009;day<sup>&#x2212;1</sup>) for 5 days every 3 weeks. On the third cycle, approximately 98&#x2009;h after starting 5-FU administration, the patient presented a transient angina-like pain with dyspnoea that disappeared with oral nitroglycerin. The EKG did not reveal specific changes, plasma cardiac enzymes and the effort-EKG were normal. 5-Fluorouracil therapy was not discontinued but the schedule was modified to 5-FU 450&#x2009;mg&#x2009;m<sup>&#x2212;2</sup> week<sup>&#x2212;1</sup> and FA 100&#x2009;mg&#x2009;tot<sup>&#x2212;1</sup>&#x2009;week<sup>&#x2212;1</sup> for 14 weeks; although transepidermal nitro-glycerin prophylaxis was not given during 5-FU administration, the patient no longer complained of anginal pain.</p>
      </sec>
    </sec>
    <sec>
      <title>DISCUSSION</title>
      <p>Relatively S-phase specific, 5-FU is a synthetic pyrimidine antimetabolite drug that has been used as a cytostatic agent in the treatment of various solid malignant tumours (adenocarcinomas, squamous cell cancer). The antitumour activity of 5-FU is exerted through several mechanisms of action and its dose, route of administration and administration schedule may play a critical role in its mechanism of action. Initially, 5-FU is inactive and is converted, within cells, into various active nucleotide forms (<xref ref-type="other" rid="bib9">Rose <italic>et al</italic>, 2002</xref>): 5-fluoro-2&#x2032;-deoxyuridine-5&#x2032;-monophosphate (FdUMP) is one of the critical nucleotide metabolites generated in tumour cells and other sensitive tissues (<xref ref-type="fig" rid="fig1">Figure 1</xref><fig id="fig1"><label>Figure 1</label><caption><p>Fluorouracil metabolism: FUR=fluorouridine; FUMP=fluorouridine-monophosphate; FUDP=fluorouridine-diphosphate; FUTP= fluorouridine-triphosphate; dU=deoxyuridine; 1=uridine phosphorylase; 2=uridine kinase; 3=orotate phosphoribosyltransferase; 4=thymidine phosphorylase; 5=thymidine kinase; 6=thymidylate synthetase.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" mime-subtype="gif" xlink:href="88-6600967f1"/></fig>).</p>
      <p>FdUMP potently inhibits thymidylate synthetase by competitive binding, resulting in a thymine-depleted state (&#x2018;thymine-less death&#x2019;). This is enhanced by folate cofactors. Cytotoxic effects are also mediated through the incorporation of fluorodeoxyuridine triphosphate into DNA (seen in continuous 5-FU infusion), and of fluorouridine-5&#x2032;-triphosphate (FUTP) and 5-fluorocytosine into RNA (seen in bolus 5-FU). Furthermore, these metabolites are also thought to alter membrane function (calcium channels), interfere with mitochondrial metabolism (energy failure phosphate balance), inhibit ribosomal RNA, alter macromolecule characteristics (contractile elements), cause oxidative damage (pyrimidines are thought to play a role in favism) and release of vasoactive substances (histamine and catecholamines are known to cause ultrastructural changes similar to doxorubicin toxicity) and induce autoimmune activity (complexes between 5-FU cells or exposure of immunogenic native compounds after cell damage) (<xref ref-type="other" rid="bib7">Norwood <italic>et al</italic>, 1993</xref>).</p>
      <p>The postulated causative mechanisms involved in 5-FU cardio-toxicity are the following: an autoimmune response to damaged cells; an increased oxygen demand in patients receiving 5-FU; a coronary spasm caused by protein kinase C-mediated vasoconstriction; dihydropyrimidine dehydrogenase deficiency (<xref ref-type="other" rid="bib5">Milano <italic>et al</italic>, 1999</xref>) and the 5-FU contaminant fluoroacetate. Inhibition of DNA synthesis, due to 5-FU incorporation into myocardial cells, was suggested to be the first step of cardiotoxicity and myocardial depression has been explained by inhibition of mitochondrial DNA synthesis due to 5-FU (<xref ref-type="other" rid="bib4">Kohne <italic>et al</italic>, 1998</xref>). Furthermore, it has been demonstrated that 5-FU may cause damage to endothelial cells with consequent thrombus formation. In our experience, 5-FU-associated effects on vascular endothelium reached their peak about 3 days from initiation of treatment, which corresponds to the clinical course of 5-FU cardiotoxicity (<xref ref-type="other" rid="bib1">Cwikiel <italic>et al</italic>, 1995</xref>,<xref ref-type="other" rid="bib2">1996</xref>).</p>
      <p>According to the analysis of 114 case reports, cardiotoxicity was experienced in 61 <italic>vs</italic> 33% of patients who received 5-FU 12-h c.i. or bolus 5-FU, respectively; 20% of the patients for whom data were available had a history of coronary artery disease or some other heart disease (<xref ref-type="other" rid="bib6">Norbertus <italic>et al</italic>, 1993</xref>). Data do not support the conclusion that dose and mode of administration of 5-FU therapy may be an important factor in the development of cardiac toxicity (<xref ref-type="other" rid="bib7">Norwood <italic>et al</italic>, 1993</xref>). Data do not support the conclusion that a history of cardiac disease increases the risks of 5-FU-induced cardiotoxicity (<xref ref-type="other" rid="bib6">Norbertus <italic>et al</italic>, 1993</xref>). CDDP frequently is combined with 5-FU, and although a synergistic effect of CDDP or carboplatin with 5-FU cannot be excluded, 5-FU therapy alone could completely explain the toxicity observed. After the chest pain appears, 5-FU treatment is usually discontinued and the response to supportive treatment with nitrates or calcium-channel blockers is good (<xref ref-type="other" rid="bib6">Norbertus <italic>et al</italic>, 1993</xref>).</p>
      <p>Many authors suggest that prophylaxis with cardioprotective agents, after development of 5-FU-associated coronary ischaemia, permits protracted 5-FU administration, where clinically indicated (<xref ref-type="other" rid="bib8">Oleksowicz and Bruckner, 1988</xref>; <xref ref-type="other" rid="bib7">Norwood <italic>et al</italic>, 1993</xref>).</p>
      <p>According to our experience, the average age of patients was 64 years, none had a history of cardiac disease, but two patients had HBP. Two patients were treated with combination therapy regimens. Apparently, 5-FU administration modality did not influence the angina-like pain presentation that appeared approximately 95&#x2009;h after starting 5-FU therapy. The angina-like syndrome disappeared with oral nitroglycerin and by stopping infusion.</p>
      <p>Since it was deemed necessary, 5-FU treatment was not discontinued in our patients. For the two patients (Cases 1 and 2) receiving nocturnal 5-FU infusion in combination therapy, the dose of 5-FU was reduced by 10&#x2013;20% and patients were given transepidermal nitroglycerine prophylaxis. 5-Fluorouracil administration modality was changed in the third patient (Case 3): the bolus schedule (5-FU 370&#x2009;mg&#x2009;m<sup>&#x2212;2</sup>&#x2009;day<sup>&#x2212;1</sup> plus FA 50&#x2009;mg&#x2009;tot<sup>&#x2212;1</sup>&#x2009;day<sup>&#x2212;1</sup> for 5 days every 3 weeks) was modified to a weekly schedule (5-FU 450&#x2009;mg&#x2009;m<sup>&#x2212;2</sup>&#x2009;week<sup>&#x2212;1</sup> and FA 100&#x2009;mg&#x2009;tot<sup>&#x2212;1</sup>&#x2009;week<sup>&#x2212;1</sup>), without prophylactic therapy.</p>
      <p>By taking the above-mentioned precautions, patients continued therapy and no longer complained of acute angina-like pain.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <ref id="bib1">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cwikiel</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Eskilsson</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Albertsson</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Stavenow</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>The influence of the 5-fluorouracil and methotrexate on vascular endothelium: an experimental study using endothelial cells in the culture</article-title>
          <source>Ann Oncol</source>
          <year>1996</year>
          <volume>7</volume>
          <fpage>731</fpage>
          <lpage>737</lpage>
          <!--PubMed citation query: 'Ann Oncol||7|731||bib1|'-->
          <pub-id pub-id-type="pmid">8905032</pub-id>
        </citation>
      </ref>
      <ref id="bib2">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cwikiel</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Eskilsson</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Wieslander</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Albertsson</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>The influence of 5-fluorouracil on the endothelium in small arteries: an electron microscopic study in rabbits</article-title>
          <source>Scanning Microsc</source>
          <year>1995</year>
          <volume>9</volume>
          <fpage>561</fpage>
          <lpage>576</lpage>
          <!--PubMed citation query: 'Scanning Microsc||9|561||bib2|'-->
          <pub-id pub-id-type="pmid">8714749</pub-id>
        </citation>
      </ref>
      <ref id="bib3">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Klaus Becker</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Erkenbrecht</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Haussinger</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Frieling</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Cardiotoxicity of the antiproliferative compound fluorouracil</article-title>
          <source>Drugs</source>
          <year>1999</year>
          <volume>57</volume>
          <supplement>4</supplement>
          <fpage>475</fpage>
          <lpage>484</lpage>
          <!--PubMed citation query: 'Drugs||57|475||bib3|'-->
          <pub-id pub-id-type="pmid">10235688</pub-id>
        </citation>
      </ref>
      <ref id="bib4">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kohne</surname>
              <given-names>C-H</given-names>
            </name>
            <name>
              <surname>Thuss-Patiench</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Friedrich</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Daniel</surname>
              <given-names>PT</given-names>
            </name>
            <name>
              <surname>Kretzschmar</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Benter</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Bauer</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Dietz</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Dorken</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Raltitrexed (Tomudex&#xAE;): an alternative drug for patients with colorectal cancer and 5-fluorouracil associated cardiotoxicity</article-title>
          <source>Br J Cancer</source>
          <year>1998</year>
          <volume>77</volume>
          <supplement>6</supplement>
          <fpage>973</fpage>
          <lpage>977</lpage>
          <!--PubMed citation query: 'Br J Cancer||77|973||bib4|'-->
          <pub-id pub-id-type="pmid">9528843</pub-id>
        </citation>
      </ref>
      <ref id="bib5">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Milano</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Etienne</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Pierrefite</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Barberi-Heyob</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Deporte-Fety</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Ren&#xE9;e N.</surname>
            </name>
          </person-group>
          <article-title>Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity</article-title>
          <source>Br J Cancer</source>
          <year>1999</year>
          <volume>79</volume>
          <supplement>3&#x2013;4</supplement>
          <fpage>627</fpage>
          <lpage>630</lpage>
          <!--PubMed citation query: 'Br J Cancer||79|627||bib5|'-->
          <pub-id pub-id-type="pmid">10027340</pub-id>
        </citation>
      </ref>
      <ref id="bib6">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Norbertus</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Pippas</surname>
              <given-names>AW</given-names>
            </name>
            <name>
              <surname>Moore</surname>
              <given-names>JO</given-names>
            </name>
          </person-group>
          <article-title>The syndrome of 5-fluorouracil cardiotoxicity: an elusive cardiopathy</article-title>
          <source>Cancer</source>
          <year>1993</year>
          <volume>71</volume>
          <supplement>2</supplement>
          <fpage>493</fpage>
          <lpage>509</lpage>
          <!--PubMed citation query: 'Cancer||71|493||bib6|'-->
          <pub-id pub-id-type="pmid">8422644</pub-id>
        </citation>
      </ref>
      <ref id="bib7">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Norwood</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Lokich</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Moore</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>The syndrome of 5-fluorouracil cardiotoxicity: an elusive cardiopathy</article-title>
          <source>Cancer</source>
          <year>1993</year>
          <volume>72</volume>
          <fpage>2287</fpage>
          <lpage>2288</lpage>
          <!--PubMed citation query: 'Cancer||72|2287||bib7|'-->
          <pub-id pub-id-type="pmid">8374889</pub-id>
        </citation>
      </ref>
      <ref id="bib8">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oleksowicz</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Bruckner</surname>
              <given-names>HW</given-names>
            </name>
          </person-group>
          <article-title>Prophylaxis of 5-fluorouracil-induced coronary vasospasm with calcium channel blockers</article-title>
          <source>Am J Med</source>
          <year>1988</year>
          <volume>85</volume>
          <fpage>750</fpage>
          <lpage>751</lpage>
          <!--PubMed citation query: 'Am J Med||85|750||bib8|'-->
          <pub-id pub-id-type="pmid">3189387</pub-id>
        </citation>
      </ref>
      <ref id="bib9">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rose</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>Farrell</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Schmitz</surname>
              <given-names>JC</given-names>
            </name>
          </person-group>
          <article-title>Thymidylate synthase: a critical target for cancer chemotherapy</article-title>
          <source>Clin Colorectal Cancer</source>
          <year>2002</year>
          <volume>1</volume>
          <supplement>4</supplement>
          <fpage>220</fpage>
          <lpage>229</lpage>
          <!--PubMed citation query: 'Clin Colorectal Cancer||1|220||bib9|'-->
          <pub-id pub-id-type="pmid">12450420</pub-id>
        </citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
